Katherine Stueland Sells 3,788 Shares of InVitae Corp (NYSE:NVTA) Stock

Share on StockTwits

InVitae Corp (NYSE:NVTA) insider Katherine Stueland sold 3,788 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $17.46, for a total transaction of $66,138.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Katherine Stueland also recently made the following trade(s):

  • On Tuesday, September 17th, Katherine Stueland sold 3,788 shares of InVitae stock. The shares were sold at an average price of $21.40, for a total transaction of $81,063.20.

InVitae stock traded up $1.33 during trading hours on Friday, hitting $18.72. The company had a trading volume of 3,854,402 shares, compared to its average volume of 1,946,333. The firm has a market cap of $1.74 billion, a PE ratio of -9.65 and a beta of 2.47. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.38 and a quick ratio of 7.38. InVitae Corp has a one year low of $9.04 and a one year high of $28.75. The firm has a 50-day moving average of $17.71 and a 200 day moving average of $21.09.

InVitae (NYSE:NVTA) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.17). The company had revenue of $56.51 million during the quarter, compared to the consensus estimate of $55.00 million. InVitae had a negative net margin of 99.49% and a negative return on equity of 58.90%. As a group, research analysts expect that InVitae Corp will post -2.44 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in NVTA. ARK Investment Management LLC grew its position in shares of InVitae by 7.9% during the 2nd quarter. ARK Investment Management LLC now owns 9,423,157 shares of the medical research company’s stock worth $221,444,000 after purchasing an additional 693,634 shares in the last quarter. Nikko Asset Management Americas Inc. grew its position in shares of InVitae by 36.9% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 7,299,703 shares of the medical research company’s stock worth $140,665,000 after purchasing an additional 1,966,915 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of InVitae by 35.8% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,223,586 shares of the medical research company’s stock worth $139,199,000 after purchasing an additional 1,905,746 shares in the last quarter. BlackRock Inc. grew its position in shares of InVitae by 19.3% during the 2nd quarter. BlackRock Inc. now owns 6,397,193 shares of the medical research company’s stock worth $150,335,000 after purchasing an additional 1,037,130 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of InVitae by 7.0% during the 2nd quarter. Vanguard Group Inc. now owns 4,535,678 shares of the medical research company’s stock worth $106,589,000 after purchasing an additional 297,356 shares in the last quarter. 91.37% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have weighed in on NVTA. Benchmark reissued a “buy” rating and issued a $28.00 price target (up from $26.00) on shares of InVitae in a report on Wednesday, August 7th. Leerink Swann set a $31.00 price target on shares of InVitae and gave the company a “buy” rating in a report on Wednesday, August 7th. Oppenheimer set a $34.00 price target on shares of InVitae and gave the company a “buy” rating in a report on Wednesday, August 7th. Chardan Capital set a $32.00 price target on shares of InVitae and gave the company a “buy” rating in a report on Sunday, August 25th. Finally, ValuEngine raised shares of InVitae from a “hold” rating to a “buy” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $27.83.

About InVitae

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.

Further Reading: What is the definition of arbitrage?

Insider Buying and Selling by Quarter for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

United Parcel Service, Inc.  Receives Average Rating of “Buy” from Brokerages
United Parcel Service, Inc. Receives Average Rating of “Buy” from Brokerages
Hanover Insurance Group  Sets New 12-Month High at $137.58
Hanover Insurance Group Sets New 12-Month High at $137.58
GlobalToken  Price Hits $0.0005 on Top Exchanges
GlobalToken Price Hits $0.0005 on Top Exchanges
Bonpay Price Down 0.4% Over Last 7 Days
Bonpay Price Down 0.4% Over Last 7 Days
Paypex Trading Up 0.8% Over Last Week
Paypex Trading Up 0.8% Over Last Week
AdultChain 1-Day Volume Tops $1.00
AdultChain 1-Day Volume Tops $1.00


 
© 2006-2019 Zolmax.